$250 million (USD) plant will help produce transformational cell and gene therapies on a global scaleCreating readiness for first production runs of potential commercial launches, including bemdaneprocel (BRT-DA01), BlueRock Therapeutics’ investigational cell therapy for Parkinson’s disease as well as product supply.